Journal of Neural Transmission

, Volume 109, Issue 2, pp 175-179

3-OMD and homocysteine plasma levels in parkinsonian patients

  • Th. MüllerAffiliated withDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Federal Republic of Germany
  • , D. WoitallaAffiliated withDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Federal Republic of Germany
  • , B. FowlerAffiliated withUniversity Children's Hospital, Basel, Switzerland
  • , W. KuhnAffiliated withDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Federal Republic of Germany

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary.

One main metabolizing pathway of levodopa is O-methylation to 3-O-methyldopa (3-OMD) by catechol-O-methyltransferase (COMT). Since COMT requires Mg2+ and S-adenosylmethionine as methyl donor for this transmethylating process, COMT converts S-adenosylmethionine to S-adenosylhomocysteine and subsequent homocysteine. Objective of this study was to demonstrate relations between plasma levodopa, 3-OMD and total homocysteine in treated parkinsonian subjects. We measured homocysteine, levodopa and 3-OMD by HPLC. We compared plasma homocysteine in two groups of treated parkinsonian subjects subdivided according to their 3-OMD level. Homocysteine was significantly (p = 0.002) elevated in the group with higher 3-OMD concentrations and positively (r = 0.52, p = 0.0006) correlated to 3-OMD. Homocysteine induces vascular disease. Previous studies showed an increase of ischaemic heart- and cerebrovascular disease in treated parkinsonian patients.

Keywords: Homocysteine 3-OMD Parkinson's disease.